Union Bridge, MD, United States of America

Ronald Hornung

This inventor holds 1 USPTO granted patent. Top assignee: The Government of the United States of America, as Represented by the. Active years: 1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald Hornung. Retrieved from https://idiyas.com/inventor/ronald-hornung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 92(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ronald Hornung: Innovator in Cancer Therapy

Introduction: Ronald Hornung is a notable inventor based in Union Bridge, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and development.

Latest Patents: Hornung holds a patent for a groundbreaking cancer therapy that utilizes interleukin-2 and flavone compounds. The patent is titled "Treatment of Cancer with Flavones and Interleukin 2," and it represents a promising approach to enhancing cancer treatment options. He has 1 patent to his name.

Career Highlights: Ronald Hornung has dedicated his career to advancing medical science, particularly in oncology. His work has been instrumental in exploring new therapeutic avenues for cancer patients.

Collaborations: Hornung has collaborated with Robert H. Wiltrout, a fellow researcher, to further enhance the impact of their work in cancer therapy.

Conclusion: Ronald Hornung's contributions to cancer treatment through his innovative patent highlight his commitment to improving patient outcomes. His work continues to inspire advancements in medical research and therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…